Literature DB >> 20002941

Proliferative drive and liver carcinogenesis: too much of a good thing?

Narci C Teoh1.   

Abstract

There have been innumerable studies published in the attempt to identify gene expression signatures in hepatocellular carcinoma (HCC). When all the regulators and targets of the differentially expressed genes are analyzed from larger studies, the most striking theme is upregulation of mitosis-promoting and cell proliferation genes in HCC compared with 'liver-specific gene clusters' in non-tumorous tissue. A major limitation of expression profiling is that it only provides a 'snapshot' of what is an evolving process and thus cannot distinguish the differences in gene expression that are primary effectors of dysregulated growth from those that represent downstream consequences. The development of HCC in a chronically diseased liver, often referred to as hepatocarcinogenesis, is a multistep process characterized by the progressive accumulation and interplay of genetic alterations causing aberrant growth, malignant transformation of liver parenchymal cells, followed by vascular invasion and metastasis. This review will discuss HCC precursor lesions, draw on the 'proliferation cluster' genes highlighted from HCC expression profiling studies, relate them to a selection of regulatory networks important in liver regeneration, cell cycle control and their potential significance in the pathogenesis of HCC or primary liver cancer.

Entities:  

Mesh:

Year:  2009        PMID: 20002941     DOI: 10.1111/j.1440-1746.2009.06121.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  8 in total

1.  Characterization of polybrominated diphenyl ether toxicity in Wistar Han rats and use of liver microarray data for predicting disease susceptibilities.

Authors:  June K Dunnick; A Brix; H Cunny; M Vallant; K R Shockley
Journal:  Toxicol Pathol       Date:  2012       Impact factor: 1.902

Review 2.  The status of zinc in the development of hepatocellular cancer: an important, but neglected, clinically established relationship.

Authors:  Leslie C Costello; Renty B Franklin
Journal:  Cancer Biol Ther       Date:  2014-01-21       Impact factor: 4.742

Review 3.  Intracellular signaling and hepatocellular carcinoma.

Authors:  Polina Iakova; Lubov Timchenko; Nikolai A Timchenko
Journal:  Semin Cancer Biol       Date:  2010-09-17       Impact factor: 15.707

4.  Hepatocellular alterations and dysregulation of oncogenic pathways in the liver of transgenic mice overexpressing growth hormone.

Authors:  Johanna G Miquet; Thomas Freund; Carolina S Martinez; Lorena González; María E Díaz; Giannina P Micucci; Elsa Zotta; Ravneet K Boparai; Andrzej Bartke; Daniel Turyn; Ana I Sotelo
Journal:  Cell Cycle       Date:  2013-02-21       Impact factor: 4.534

5.  Aberrant DNA methylation of imprinted loci in hepatocellular carcinoma and after in vitro exposure to common risk factors.

Authors:  Hector Hernandez-Vargas; Zdenko Herceg; Marie-Pierre Lambert; Pierre-Benoit Ancey; Davide Degli Esposti; Marie-Pierre Cros; Athena Sklias; Jean-Yves Scoazec; David Durantel
Journal:  Clin Epigenetics       Date:  2015-02-27       Impact factor: 6.551

6.  SAG-UPS attenuates proapoptotic SARM and Noxa to confer survival advantage to early hepatocellular carcinoma.

Authors:  S C Chang; W Q W Choo; H C Toh; J L Ding
Journal:  Cell Death Discov       Date:  2015-09-28

7.  Ceramide synthase-4 orchestrates the cell proliferation and tumor growth of liver cancer in vitro and in vivo through the nuclear factor-κB signaling pathway.

Authors:  Jinwu Chen; Xiaojie Li; Dengjiao Ma; Tao Liu; Pingping Tian; Chuanfang Wu
Journal:  Oncol Lett       Date:  2017-06-09       Impact factor: 2.967

8.  Pomegranate Bioactive Constituents Suppress Cell Proliferation and Induce Apoptosis in an Experimental Model of Hepatocellular Carcinoma: Role of Wnt/ β -Catenin Signaling Pathway.

Authors:  Deepak Bhatia; Roslin J Thoppil; Animesh Mandal; Karishma A Samtani; Altaf S Darvesh; Anupam Bishayee
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-28       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.